Senior Correspondent, London
Ben's Feed
Jan 7, 2015

Novartis taps into gene editing for next generation drugs

LONDON, Jan 7 (Reuters) – Novartis is diving
deeper into the world of gene-based medicine by signing deals
with two U.S. biotech companies, giving it access to a powerful
new genome editing technology.

The tie-ups with unlisted Intellia Therapeutics and Caribou
Biosciences show the Swiss drugmaker’s confidence in the
potential of so-called CRISPR technology, both for making new
medicines and as a research tool.

Jan 6, 2015

J&J, Bavarian Nordic start clinical tests in Ebola vaccine race

LONDON (Reuters) – Johnson & Johnson has started clinical trials of its experimental Ebola vaccine, which uses a booster from Denmark’s Bavarian Nordic, making it the third such shot to enter human testing.

The initiation of the Phase I study in Britain, which had been expected about now, marks further progress in the race to develop a vaccine against a disease that has killed more than 8,000 people in West Africa since last year.

Jan 6, 2015
Jan 6, 2015

J&J and Bavarian Nordic start clinical tests of Ebola vaccine

LONDON, Jan 6 (Reuters) – Johnson & Johnson has
started clinical trials of its experimental Ebola vaccine, which
uses a booster from Denmark’s Bavarian Nordic, making
it the third such shot to enter human testing.

The initiation of the Phase I study, which had been expected
about now, marks further progress in the race to develop a
vaccine against a disease has killed more than 8,000 people in
West Africa since last year.

Jan 1, 2015
Jan 1, 2015
Jan 1, 2015

Pharma and biotech on a roll as drug approvals hit 18-year high

LONDON, Jan 1 (Reuters) – U.S. drug approvals in 2014 hit
their highest level in 18 years and recommendations in Europe
also came at a rapid rate, driven by expensive new treatments
for cancer and rare diseases.

After suffering a wave of patent losses on blockbuster
products, which peaked two years ago, drugmakers are recovering
their ability to bring new medicines to market and productivity
is improving.

Dec 22, 2014
Dec 19, 2014
Dec 19, 2014
    • About Ben

      "Ben Hirschler is European pharmaceuticals, biotechnology and healthcare correspondent, based in London. Previously, he was in charge of British company news and before that was posted to Johannesburg, covering the economic challenges facing post-apartheid South Africa."
    • More from Ben

    • Follow Ben